Senti Bio reports encouraging SENTI-202 AML trial results as the FDA grants RMAT status, with strong response rates, durable ...
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high ...
This approach offers an enhanced therapeutic effect with minimal systemic toxicity, addressing one of oncology’s ...
Based on the response data, coupled with the supportive IFN- <GAMMA> biomarker data, Pliant plans to accelerate the development of PLN-101095 with the initiation of a Phase 1b indication expansion ...
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting ...
GTA182 demonstrates favorable safety, dose-proportional pharmacokinetics, robust PRMT5 pathway inhibition, and encouraging ...
Obesity is the excessive or abnormal accumulation of fat or adipose tissue in the body that impairs health via its ...
Placebo-controlled Phase 2 study will evaluate SAT-3247 treatment over three months among ambulatory children with Duchenne- Study endpoints include safety and tolerability, effect on muscle force and ...
The Phase 1/2a clinical trial will assess the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ABS-201. Interim data are expected in the second half ...
ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025 -- Updated ...
Kymera Therapeutics, Inc. ( KYMR) Citi Annual Global Healthcare Conference 2025 December 3, 2025 11:15 AM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback